Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun 5:9:284.
doi: 10.3389/fendo.2018.00284. eCollection 2018.

Diabetes Mellitus Secondary to Cushing's Disease

Affiliations
Review

Diabetes Mellitus Secondary to Cushing's Disease

Mattia Barbot et al. Front Endocrinol (Lausanne). .

Abstract

Associated with important comorbidities that significantly reduce patients' overall wellbeing and life expectancy, Cushing's disease (CD) is the most common cause of endogenous hypercortisolism. Glucocorticoid excess can lead to diabetes, and although its prevalence is probably underestimated, up to 50% of patients with CD have varying degrees of altered glucose metabolism. Fasting glycemia may nevertheless be normal in some patients in whom glucocorticoid excess leads primarily to higher postprandial glucose levels. An oral glucose tolerance test should thus be performed in all CD patients to identify glucose metabolism abnormalities. Since diabetes mellitus (DM) is a consequence of cortisol excess, treating CD also serves to alleviate impaired glucose metabolism. Although transsphenoidal pituitary surgery remains the first-line treatment for CD, it is not always effective and other treatment strategies may be necessary. This work examines the main features of DM secondary to CD and focuses on antidiabetic drugs and how cortisol-lowering medication affects glucose metabolism.

Keywords: Cushing’s disease; cortisol-lowering medication; diabetes; glucocorticoids; insulin resistance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The main mechanisms of action in glucocorticoid-induced diabetes and their effects on target tissues in Cushing’s disease.

References

    1. Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing’s syndrome. Lancet (2015) 386(9996):913–27. 10.1016/S0140-6736(14)61375-1 - DOI - PubMed
    1. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest (2009) 39(2):81–93. 10.1111/j.1365-2362.2008.02067.x - DOI - PubMed
    1. Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol (2016) 4(7):611–29. 10.1016/S2213-8587(16)00086-3 - DOI - PubMed
    1. Scaroni C, Zilio M, Foti M, Boscaro M. Glucose metabolism abnormalities in Cushing syndrome: from molecular basis to clinical management. Endocr Rev (2017) 38(3):189–219. 10.1210/er.2016-1105 - DOI - PubMed
    1. Zilio M, Barbot M, Ceccato F, Camozzi V, Bilora F, Casonato A, et al. Diagnosis and complications of Cushing’s disease: gender-related differences. Clin Endocrinol (Oxf) (2014) 80(3):403–10. 10.1111/cen.12299 - DOI - PubMed

LinkOut - more resources